Latest News for Epsilon Healthcare Stock (OTC:HDRPF)

Epsilon Healthcare Ltd is a diversified global healthcare and pharmaceuticals company. It owns number of medicinal cannabis assets including the cannabis manufacturing facility in the Southern Hemisphere, the Tetra Health clinic, and the Medimar Platform an end to end ecommerce solution for nutraceuticals and cannabis. EPN additionally operates a turn-key cannabis cultivation solutions provider based in Vancouver, Canada.

News

Intraday Update

Markets

Movers

Trading Ideas

ACSAY

ACTG

ALLO

AMSC

ANAT

APTS

ATONY

AVNS

BOXS

BRDCY

BRID

BRRAY

BSAC

CALM

CATC

CBDL

CEQP

CHFS

CNDT

CNTMF

CORE

CVGI

DFIN

DLTR

DYLLF

EGLE

ELGX

ENDO

ENTA

EVTI

FCBC

FCUUF

FQVTF

FRBK

GALKF

GALT

GLBS

GLOG

GMLP

GPOR

GRNH

GVXXF

HAYN

HDRPF

HRTG

HRVOF

HSNGF

IMAX

ISUZY

JAPSY

JNPR

KELYA

KLXE

KRKR

LFCOF

LKCO

LQDT

LSDAF

LTRPA

MCHVY

MFCSF

MGPI

MGYOY

MKGI

MNRO

MTST

NEAPF

NGVT

NHTC

NOVN

Stocks That Hit 52-Week Lows On Thursday

EPSILON HEALTHCARE LTD by Epsilon Healthcare Limited

Epsilon Healthcare Ltd

<p>BMO Capital  analyst Jeffrey Silber   maintains Strategic Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRA#NASDAQ">STRA</a>) with a Outperform and raises the price target from $123 to $130.</p>


Price Target

Analyst Ratings

STRA

BMO Capital Maintains Outperform on Strategic Education, Raises Price Target to $130

ZVSA

ZyVersa Therapeutics Shares Resume Trade Following Circuit Breaker Halt

<p>RBC Capital  analyst Ben Hendrix   maintains HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) with a Outperform and raises the price target from $322 to $329.</p>


RBC Capital Maintains Outperform on HCA Healthcare, Raises Price Target to $329

<p>BMO Capital  analyst Fadi Chamoun   maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Market Perform and lowers the price target from $575 to $490.</p>


SAIA

BMO Capital Maintains Market Perform on Saia, Lowers Price Target to $490

<p>Yahoo recently acquired Artifact, an artificial intelligence (AI)-driven news aggregation and discovery platform. </p>
<p>Founded in 2023 by Instagram Co-Founders Kevin Systrom and Mike Krieger, Artifact quickly gained popularity, earning the title Everyday Essential App of the Year from the Google Play Store.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong></strong><strong>This Uber-for-moving startup is quietly taking the world by storm,<a href="https://www.benzinga.com/money/muvr"><strong> </strong><strong>here&#8217;s how anyone can invest for a limited time</strong></a>.</strong></li>
<li><strong></strong><strong>Amid the ongoing EV revolution, previously overlooked low-income communities<a href="https://www.benzinga.com/money/dunamis-1"><strong> </strong><strong>now harbor a huge investment opportunity</strong></a>.</strong></li>
</ul>
<p>Despite its early success, Artifact struggled to maintain its growth trajectory in the rapidly evolving AI landscape. In January, the founders announced their intention to shut down the company, citing insufficient market opportunities to justify further investment. This highlights both the volatility and <a href="https://www.benzinga.com/alternative-investments/startups">lucrative nature of startups and venture capital</a>.&nbsp;</p>
<p>"We launched a year ago, and since then, we've been working tirelessly to build a great product. We have built something that a core group of users love, but we have concluded that the market opportunity isn't big enough to warrant continued investment in this way," Systrom said via a <a href="https://medium.com/artifact-news/shutting-down-artifact-1e70de46d419">Medium Post</a>.&nbsp;</p>
<p><strong>Trending: Invest like a millionaire. Exclusive opportunity to<a href="https://www.benzinga.com/money/epic-games"><strong> </strong><strong>invest in Epic Games $17 billion gaming empire.</strong></a></strong></p>
<p>Despite this setback, Yahoo stepped in to acquire Artifact shortly after the shutdown announcement. Under the new arrangement, Artifact will cease to operate as a standalone app. Instead, its proprietary AI-powered personalization technology will be integrated into Yahoo&#8217;s broader suite of services, including the Yahoo News app.</p>
<p>"Yahoo was one of the first to combine human and algorithmic curation of news. Since then, the landscape of machine learning and personalization has changed dramatically, and Artifact has innovated with best-in-class technology to meet the moment," said Kat Downs Mulder, senior vice president and general manager of Yahoo News. "Artifact has become a beloved product, and we're thrilled to be able to continue to grow that technology and further our mission of becoming the trusted guide to digital information and the best curator connecting people to the content that matters most to them."</p>
<p>With Artifact, Yahoo News will be able to provide a more personalized feed of news stories to its readers in addition to easy access to top news, link-sharing capabilities and tools to prevent clickbait proliferation.</p>
<p>The terms of the deal have not been disclosed.&nbsp;</p>
<p><strong>Keep Reading <a href="https://www.benzinga.com/alternative-investments/startups"><strong>About Startups</strong></a>:</strong></p>
<ul>
<li><strong></strong><strong>Retail invested +$2 million in this<a href="https://www.benzinga.com/money/gameflip-2"><strong> </strong><strong>tech-forward startup taking on a $272 billion industry</strong></a>.</strong></li>
<li><strong></strong><strong>This startup coined &#8220;eBay for gamers&#8221; with a breathtaking track record has opened up<a href="https://www.benzinga.com/money/gameflip-2"><strong> a window to invest in its future growth</strong></a>.</strong></li>
</ul>
<p>Systrom and Krieger will assist Yahoo in an advisory capacity to facilitate technology integration. The duo is well-known for their previous collaboration in founding Instagram in 2010, which they sold to Facebook in 2012 for $1 billion in a stock and cash deal</p>


General

Yahoo Acquired Social AI App Artifact From Instagram's Founders Just After The App Was Almost Shut Down

Contracts

U.S. Air Force Has Awarded Boeing A $178M Contract To Produce Seven MH-139A Aircraft And Provide Sustainment And Training Support

<p><i><strong>Spanish partner to contribute to European GEM-T missile development and production</strong></i></p>
<p>TUCSON, Ariz., April 29, 2024 /PRNewswire/ -- Raytheon, an RTX business (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>), has awarded Spanish supplier, Sener, a contract to develop and produce the electro-mechanical control section of the Patriot&#xAE; GEM-T missile. Sener will directly contribute to missile production in Europe in support of the recently awarded GEM-T contract by the NATO Support and Procurement Agency (NSPA) for a quantity of up to 1,000 missiles for a coalition of nations, including Germany, the Netherlands, Romania and Spain.</p>
<p>"Sener will play a critical role in supporting our expansion of GEM-T missile production capacity in Europe," said Pete Bata, vice president of Global Patriot at Raytheon. "Together with our broad – and growing – network of suppliers in the region, we are moving forward to increase this critical air defense missile inventory in support of NATO and our European Patriot allies."</p>
<p>Sener is a private engineering and technology group with a demonstrated expertise in the design and production of missile actuation and control system technologies. Sener will work with Raytheon's engineering experts to co-develop the critical GEM-T missile control section component, which will then be produced locally at Sener's site in Tres Cantos, Madrid.</p>
<p>"We are delighted to receive Raytheon's trust in this important contract which consolidates Sener's role as an international center of excellence in the design and manufacturing of missile actuation and control systems," said Rafael Orbe, general director of Defense at Sener. "The Spanish defense industry has high technological capacities, and we are proud to put it at the service of Raytheon, our armed forces, and NATO allies."</p>
<p>GEM-T, the Patriot Advanced Capability 2 (PAC-2) missile interceptor enhanced for defeating tactical ballistic missiles, is a primary effector for the combat-proven Patriot air and missile defense system. The world's battle-proven air and missile defense system, Patriot is relied upon by 19 countries - eight European nations, and Ukraine - for defense against cruise missiles, ballistic missiles, and enemy drones and aircraft.</p>


Global

RTX's Raytheon Awards Contract To Spain's Sener For A Quantity Of Up To 1,000 Missiles For A Coalition Of Nations

<ul>
<li>Apple has planned a digital launch event for May 7.</li>
<li>Investors are closely watching to see if the upcoming product launches will provide the momentum needed for Apple&#39;s stock to rebound.</li>
</ul>
<p>&nbsp;</p>
<p>With a digital launch event scheduled for May 7, Apple Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) is on the verge of some interesting developments, especially with its iPad lineup. Enhancements to the iPad Pro and a potential size increase for the iPad Air are highly anticipated.</p>
<p>Additionally, a refresh of the iPhone lineup with new colors is expected, which is always a hit with consumers. There will also be announcements at Apple&#39;s Worldwide Developers Conference (WWDC) in June, where the focus on artificial intelligence (AI) could lead to groundbreaking advancements in AI technology, enriching Apple&#39;s product ecosystem or introducing innovative AI-centric services.</p>
<p>Apple&#39;s upcoming launches arrive at a pivotal moment for the company, with its stock performance experiencing volatile periods. Since July 2023, Apple&#39;s shares have been caught in a consolidation phase, moving between $165 and $200.</p>
<p>As of now, the stock is lingering around the $165 level, which is a critical support area. So far, 2024 has posed challenges for Apple, with its stock taking a 12% decline. A stark contrast to the impressive 48% surge seen in 2023.</p>
<p><img alt="2024-04-26_22-01-36.jpg" src="https://www.benzinga.com/files/u517520/2024-04-26_22-01-36.jpg" style="height:345px; width:624px" /></p>
<p>Investors are keen to see if the new product launches could be the catalyst Apple&#39;s stock needs to rebound from support to revisit the all-time high.</p>
<p>The question now is whether Apple can break through the solid $200 resistance level and chart a new trajectory for its stock in the upcoming months.</p>
<p>After the closing bell on Friday, April 26, the stock closed at $169.30, trading down by 0.35%.</p>
<p>&nbsp;</p>
<p class="contributor-disclaimer"><em>This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.</em></p>


Tech

AAPL

Apple's Imminent Product Launches Aims to Revitalize Its Stock After a 12% Decline in 2024, Potentially Setting a New Course for Investors

<p>By <a href="https://roboforex.com/?utm_source=benzinga.com&amp;utm_medium=pr&amp;utm_campaign=rf_en_external_article_29042024&amp;utm_content=analysis&amp;utm_term=forecast">RoboForex</a> Analytical Department</p>
<p>The USD/JPY pair is hovering around 155.00 on Monday, having earlier touched a new 34-year peak at 160.00. Market rumours suggest that the Japanese authorities might have intervened in the currency market, although there has been no official confirmation. Today&#39;s market movement is particularly notable due to a public holiday in Japan, which has resulted in minimal market liquidity. This scenario made it relatively easy for investors to prompt significant changes in the quotes.</p>
<p>Last week, the Bank of Japan (BoJ) maintained its monetary policy foundation, keeping the interest rate steady at 0-0.1% per annum. Market participants were left disappointed, as they had anticipated a more pronounced reaction from the BoJ.</p>
<p>The primary driver of the yen&#39;s ongoing weakness is the significant discrepancy between the interest rates set by the BoJ and the US Federal Reserve. This interest rate gap exerts substantial pressure on the yen, making any actual intervention largely ineffective. The BoJ, aware of this reality, has thus far limited its actions to verbal interventions to influence the yen&#39;s value.</p>
<h3><strong>Technical Analysis Of USD/JPY</strong></h3>
<p><a href="https://www.benzinga.com/files/u117641/usdjpyh4_13.png"><img alt="" src="https://www.benzinga.com/files/u117641/usdjpyh4_13.png" style="height:280px; width:624px" /></a></p>
<p>On the H4 chart of USD/JPY, a growth wave reaching the level of 160.16 was realised. The structure of the first impulse of decline to 154.70 is currently forming. Once this level is reached, a correction to 157.35 (testing from below) is anticipated, potentially followed by a new wave of decline towards 152.32, with the prospect of continuing the trend to 149.65. This scenario is technically supported by the MACD oscillator, which is positioned above zero at the highs but is expected to decline to new lows.</p>
<p><a href="https://www.benzinga.com/files/u117641/usdjpyh1_11.png"><img alt="" src="https://www.benzinga.com/files/u117641/usdjpyh1_11.png" style="height:280px; width:624px" /></a></p>
<p>On the H1 chart, the upward growth wave to 160.16 has been completed. We are now observing the formation of the first impulse of the decline wave. The local target of this downside impulse at 155.15 has been achieved. We anticipate a corrective move to 157.35 (testing from below). Subsequently, the next phase of the downward trend to 154.65 is expected, which is the primary target. After completing this, a correction back to 157.35 may be considered. The Stochastic oscillator confirms this bearish outlook, with its signal line below 50 and pointing strictly downwards.</p>
<p>Disclaimer</p>
<p><em>Any forecasts contained herein are based on the author&#39;s particular opinion. This analysis may not be treated as trading advice. </em><em>RoboForex bears no responsibility for trading results based on trading recommendations and reviews contained herein.</em></p>
<p class="contributor-disclaimer"><em>This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.</em></p>


Asia

Technicals

Forex

Japanese Yen Shows Volatility Amid Speculation Of Intervention

<p>When it comes to cancer, there&rsquo;s innovation both on the diagnostics and the&nbsp;treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as it allowed pharmaceutical companies like Pfizer Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) and Moderna Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) to develop their groundbreaking&nbsp;vaccines in record time. By the looks of it, this was&nbsp;only the beginning of the healthcare revolution that mRNA triggered.&nbsp;</p>
<p>Mainz Biomed N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mynz#NASDAQ">MYNZ</a>)&nbsp;to revolutionize colorectal cancer&nbsp;diagnostics and prevention.</p>
<p>CRC has been recognized as the second most lethal cancer both in the U.S. and Europe. However, it is also among the most preventable ones as early detection results in&nbsp;survival rates above 90%.</p>
<p>A company specialized in molecular genetics diagnostic, Mainz Biomed,&nbsp;whose&nbsp;flagship product, ColoAlert&reg;, a CRC screening test already showed its ability to detect even pre-cancerous polyps known as advanced adenomas thanks to mRNA biomarkers,&nbsp;just announced significant findings from a pooled clinical study as its flagship project undergoes a pivotal FDA clinical study for U.S. regulatory approval.&nbsp;</p>
<p>Mainz Biomed&nbsp;conducted this study to fine tune and evaluate novel mRNA biomarkers&nbsp;along with&nbsp;proprietary AI algorithm for integration into pivotal FDA PMA clinical trial for its next-generation CRC screening tool.&nbsp;</p>
<p>By analyzing 690 subjects, including new patients from Mainz Biomed&#39;s ColoFuture and eAArly DETECT trials across 30 clinical sites in the U.S. and Europe, Mainz&nbsp;reported topline results that confirm the positive&nbsp;results it had previously reported.&nbsp;The study&#39;s topline results showcased a sensitivity of 92% and a specificity of 90% for CRC detection, as well as an 82% sensitivity for advanced adenoma. Mainz Biomed conducted the evaluations by using its novel mRNA biomarkers, a fecal immunochemical test (FIT), and a proprietary AI algorithm. When announcing the results, Mainz Biomed CEO Guido Baechler announced these results mark a critical milestone towards the company&rsquo;s FDA PMA pivotal study, ReconAAsense. Mainz Biomed plans to report the findings of the study at a major medical conference during the second quarter of 2024.</p>
<p>With the help of mRNA, promising new treatments have emerged.&nbsp;</p>
<p>With the power to detect a pre-cancerous stage, Mainz Biomed is able to revolutionize the CRC diagnostics field. With the power of a mRNA cancer vaccine that Moderna developed with Merck, patients&rsquo; bodies could get a personalized instruction on how to fight cancer, targeting and destroying only cancer cells. Therefore, the potential of mRNA in fighting cancer cannot be overstated as mRNA promises to revolutionize both cancer diagnostics and treatment.&nbsp;</p>
<p>Moderna and OpenAI to exploit AI&rsquo;s potential to advance mRNA medicine.</p>
<p>Since its beginnings, Moderna has leveraged the power of machine learning and its is the first of its peers to embrace the digital world since its inception. It embarked on a venture with OpenAI early last year, with the launch of a customized version of ChatGPT, mChat. Purpose built GPTs are now an integral part of its business units.&nbsp;On Wednesday, Moderna announced the deepening of the partnership to advance the future of mRNA medicine.&nbsp;</p>
<p>By the looks of it, mRNA promises a new era for healthcare.&nbsp;</p>
<p><em>DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.</em></p>
<p class="contributor-disclaimer"><em>This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.</em></p>


Biotech

Penny Stocks

Health Care

MRNA

MYNZ

mRNA Is Promising A Breakthrough In Fighting Cancer

<p>EV giant <strong>Tesla Inc</strong>&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Model 3 and Model Y have been deemed in compliance with China&#8217;s data security requirements by a Chinese auto association, marking a significant stride towards the deployment of its full self-driving (FSD) driver assistance software in the world&#8217;s largest EV market.</p>
<p><strong>What Happened:</strong> The China Association of Automobile Manufacturers (CAAM) on Sunday said in a statement that 76 models of six companies including BYD, Ideal, Lotus, Hezhong New Energy, Tesla, and NIO met the compliance requirements for automotive data security. </p>
<p>Both Tesla&#8217;s locally made Model 3 and Y were among the vehicles that met the requirements. The two models are Tesla&#8217;s mass-market offerings with their lower price point as compared to its other models. </p>
<p><strong>Why It Matters:</strong> Data security was one of the concerns that prevented the deployment of Tesla&#8217;s FSD software in China. Chinese regulators previously mandated that all data collected by its vehicles in China be <a href="https://www.benzinga.com/news/23/08/33852607/tesla-sets-record-straight-on-sentinel-mode-privacy-in-china-all-data-generated-by-vehicles-will-be">stored within the country</a>, leaving it unable to transfer any back to the United States. </p>
<p>The company is now looking for permission to transfer driving data overseas, Reuters reported on Monday, citing a person familiar with the matter. </p>
<p>The development comes on the heel of company CEO <strong>Elon Musk</strong>&#8216;s previously unannounced trip to China over the weekend. Tesla has also <a href="https://www.benzinga.com/markets/asia/24/04/38481213/breaking-tesla-reportedly-teams-up-with-baidu-to-roll-out-fsd-in-china" target="_blank" rel="noreferrer noopener">partnered with Beijing-based internet company&nbsp;<strong>Baidu Inc</strong></a>&nbsp;for lane-level mapping and navigation data for China, crucial to deploying FSD in the country.</p>
<p><strong>The Wall Street Journal</strong> on Monday also <a href="https://www.wsj.com/tech/tesla-wins-chinas-backing-for-driver-assistance-service-20816802">reported</a> that Chinese officials have tentatively approved the company&#8217;s plan to launch FSD in the East Asian country. </p>
<p><em>Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.</em></p>
<p><em><strong>Read More:</strong></em> <em><a href="https://www.benzinga.com/news/24/04/38483089/after-china-tesla-announces-european-tour-for-cybertruck-despite-sales-being-limited-to-us" target="_blank" rel="noreferrer noopener">After China, Tesla Announces European Tour For Cybertruck Despite Sales Being Limited To US</a></em></p>
<p><em>Photo via Shutterstock</em></p>


TSLA

Tesla's Model 3 And Model Y Clear China's Data Security Hurdle, FSD Software Deployment Nears

<p>Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Avantor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) in the last three months.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $27.9, a high estimate of $30.00, and a low estimate of $25.00. Observing a 9.41% increase, the current average has risen from the previous average price target of $25.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399304_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Avantor by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Justin Bowers</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Daniel Brennan</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$29.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$30.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$29.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$29.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Avantor. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Avantor compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Avantor's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Avantor's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AVTR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Avantor analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Avantor</h2>
<p>Avantor Inc is involved in providing products and services to biopharma, healthcare, education and government, and advanced technologies and applied materials industries. The company's offerings include materials and consumables, equipment and instrumentation and services and specialty procurement. Its brand profile consists of NuSil, RANKEM, POCH, BeneSphera, and Macron Fine Chemicals among others. The firm operates in three geographical segments namely Americas, Europe, and AMEA. It generates a majority of its revenue from the Americas.</p>
<h3>Unraveling the Financial Story of Avantor</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Avantor's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately <strong>-4.02%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>5.72%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Avantor's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>1.9%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.76%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.05</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AVTR

Beyond The Numbers: 10 Analysts Discuss Avantor Stock

<p><i>Data Now Available on Company Website Following 8-K Filing</i><br /><br />&nbsp;</p>
<p><i>Data Demonstrate that Treatment with TFF TAC Prevents Lung Transplant Rejection at Only One-sixth of the Dose of Oral Tacrolimus and at Two-thirds of the Oral Tacrolimus Systemic Trough Exposures</i></p>
<p><i>Gene Expression Biomarker Data Demonstrate that Treatment with TFF TAC Leads to Normalization of Expression of Rejection-Related Genes</i></p>
<p>FORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) ("the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that data from the Company's ongoing Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for the prevention of lung transplant rejection is available on the Company's website. These data were recently presented by Professor Gregory Snell, the lead Principal Investigator of the TFF TAC Phase 2 study, via an oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 44th&nbsp;Annual Meeting during a late breaking clinical science abstract session on April 13, 2024. The data became available following the Company's 8-K filing.</p>
<p>"Following the presentation of these updated data from our ongoing Phase 2 study of TFF TAC at this year's ISHLT meeting, we have received highly positive feedback from the transplant medicine community, indicating heightened awareness of this innovative program and a growing enthusiasm for its potential to improve upon the current standard of care," said Harlan Weisman, Chief Executive Officer of TFF Pharmaceuticals. "Looking ahead, we are focused on advancing this highly innovative program into potentially registrational testing, and we look forward to sharing additional data from the TFF TAC Phase 2 trial later this year."</p>
<p>"These unprecedented results from our Phase 2 study provide evidence that TFF TAC has the potential to optimize lung immune suppression at decreased systemic exposures. TFF TAC can prevent rejection of the transplanted lung when delivered at only one-sixth of the oral tacrolimus dose and at two-thirds of the oral tacrolimus systemic trough exposures, levels predicted to decrease systemic toxicities," said Dr. Zamaneh Mikhak, Chief Medical Officer of TFF Pharmaceuticals. "In addition, our gene expression data demonstrate that TFF TAC normalizes the expression of genes associated with lung transplant rejection in patients whose systemic exposures are decreased, providing evidence at a molecular level that treatment with TFF TAC can increase lung immune suppression at reduced systemic exposures. These data collectively point to the potential opportunity to improve efficacy as well as safety after lung transplantation with TFF TAC."</p>


TFFP

TFF Pharmaceuticals Makes Available Phase 2 Data From Tacrolimus Inhalation Powder For The Prevention Of Lung Transplant Rejection Presented At The Recent ISHLT Annual Meeting

<p>Deep-pocketed investors have adopted a bullish approach towards Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SQ usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Block. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 60% leaning bullish and 40% bearish. Among these notable options, 3 are puts, totaling $384,780, and 7 are calls, amounting to $368,741.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $65.0 and $100.0 for Block, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Block's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Block's substantial trades, within a strike price spectrum from $65.0 to $100.0 over the preceding 30 days.</p>
<h3>Block Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399301_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SQ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/03/24</td>
<td>$4.1</td>
<td>$4.05</td>
<td>$4.05</td>
<td>$75.00</td>
<td>$235.3K</td>
<td>496</td>
<td style="text-align: right;">14</td>
</tr>
<tr>
<td>SQ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.45</td>
<td>$8.35</td>
<td>$8.35</td>
<td>$65.00</td>
<td>$107.7K</td>
<td>302</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>SQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$1.44</td>
<td>$1.4</td>
<td>$1.44</td>
<td>$87.50</td>
<td>$88.9K</td>
<td>2.2K</td>
<td style="text-align: right;">645</td>
</tr>
<tr>
<td>SQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/31/24</td>
<td>$1.49</td>
<td>$1.29</td>
<td>$1.5</td>
<td>$90.00</td>
<td>$75.0K</td>
<td>28</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>SQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$1.39</td>
<td>$1.38</td>
<td>$1.39</td>
<td>$100.00</td>
<td>$59.3K</td>
<td>1.3K</td>
<td style="text-align: right;">852</td>
</tr>
</tbody>
</table>
</p>
<h3>About Block</h3>
<p>Founded in 2009, Block provides payment services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. In 2023, Square's payment volume was a little over $200 million.</p>
<p>Following our analysis of the options activities associated with Block, we pivot to a closer look at the company's own performance.</p>
<h3>Block's Current Market Status</h3>
<ul>
<li>With a volume of 688,551, the price of SQ is up 0.23% at $74.65. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 3 days.</li>
</ul>
<h3>Expert Opinions on Block</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $92.6.</p>
<ul>
<li>Consistent in their evaluation, an analyst from Baird keeps a Outperform rating on Block with a target price of $98. </li>
<li>An analyst from Susquehanna persists with their Positive rating on Block, maintaining a target price of $100. </li>
<li>Maintaining their stance, an analyst from Mizuho continues to hold a Buy rating for Block, targeting a price of $106. </li>
<li>Reflecting concerns, an analyst from Morgan Stanley lowers its rating to Underweight with a new price target of $60.</li>
<li>An analyst from Benchmark persists with their Buy rating on Block, maintaining a target price of $99. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Block with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Smart Money Is Betting Big In Block Options

<p>Financial giants have made a conspicuous bullish move on GE Aero. Our analysis of options history for GE Aero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) revealed 13 unusual trades.</p>
<p>Delving into the details, we found 61% of traders were bullish, while 15% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $117,870, and 10 were calls, valued at $962,504.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $120.0 to $230.0 for GE Aero during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of GE Aero stands at 602.25, with a total volume reaching 2,546.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in GE Aero, situated within the strike price corridor from $120.0 to $230.0, throughout the last 30 days.</p>
<h3>GE Aero Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399296_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>GE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/17/24</td>
<td>$3.85</td>
<td>$3.8</td>
<td>$3.8</td>
<td>$165.00</td>
<td>$218.7K</td>
<td>1.6K</td>
<td>83</td>
</tr>
<tr>
<td>GE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/07/24</td>
<td>$1.59</td>
<td>$1.5</td>
<td>$1.5</td>
<td>$180.00</td>
<td>$150.0K</td>
<td>103</td>
<td>1.2K</td>
</tr>
<tr>
<td>GE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/03/24</td>
<td>$7.0</td>
<td>$6.2</td>
<td>$6.9</td>
<td>$157.50</td>
<td>$138.0K</td>
<td>852</td>
<td>200</td>
</tr>
<tr>
<td>GE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/24/24</td>
<td>$45.65</td>
<td>$45.25</td>
<td>$45.65</td>
<td>$120.00</td>
<td>$132.3K</td>
<td>0</td>
<td>17</td>
</tr>
<tr>
<td>GE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$29.55</td>
<td>$27.2</td>
<td>$28.11</td>
<td>$160.00</td>
<td>$87.0K</td>
<td>457</td>
<td>30</td>
</tr>
</tbody>
</table>
</p>
<h3>About GE Aero</h3>
<p>GE Aerospace is the global leader in designing, manufacturing, and servicing large aircraft engines, along with partner Safran in their CFM joint venture. With its massive global installed base of nearly 70,000 commercial and military engines, GE Aerospace earns most of its profits on recurring service revenue of that equipment, which operates for decades. GE Aerospace is the remaining core business of the company formed in 1892 with historical ties to American inventor Thomas Edison; that company became a storied conglomerate with peak revenue of $130 billion in 2000. GE spun off its appliance, finance, healthcare, and wind and power businesses between 2016 and 2024.</p>
<p>After a thorough review of the options trading surrounding GE Aero, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>GE Aero's Current Market Status</h3>
<ul>
<li>Trading volume stands at 602,952, with GE's price up by 1.48%, positioned at $164.76.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 85 days.</li>
</ul>
<h3>Professional Analyst Ratings for GE Aero</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $176.2.</p>
<ul>
<li>An analyst from Citigroup has decided to maintain their Buy rating on GE Aero, which currently sits at a price target of $186. </li>
<li>An analyst from RBC Capital has decided to maintain their Outperform rating on GE Aero, which currently sits at a price target of $160. </li>
<li>An analyst from Argus Research has decided to maintain their Buy rating on GE Aero, which currently sits at a price target of $180. </li>
<li>Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on GE Aero with a target price of $165. </li>
<li>An analyst from Deutsche Bank has decided to maintain their Buy rating on GE Aero, which currently sits at a price target of $190. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for GE Aero, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Behind the Scenes of GE Aero's Latest Options Trends

<p>Financial giants have made a conspicuous bullish move on Citigroup. Our analysis of options history for Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) revealed 12 unusual trades.</p>
<p>Delving into the details, we found 75% of traders were bullish, while 0% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $4,538,400, and 10 were calls, valued at $631,131.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $75.0 for Citigroup during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Citigroup's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Citigroup's significant trades, within a strike price range of $50.0 to $75.0, over the past month.</p>
<h3>Citigroup Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399290_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/03/24</td>
<td>$12.6</td>
<td>$11.25</td>
<td>$12.0</td>
<td>$75.00</td>
<td>$3.6M</td>
<td>0</td>
<td>3.0K</td>
</tr>
<tr>
<td>C</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$3.45</td>
<td>$3.35</td>
<td>$3.4</td>
<td>$60.00</td>
<td>$938.4K</td>
<td>546</td>
<td>3.0K</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$1.54</td>
<td>$1.5</td>
<td>$1.54</td>
<td>$62.00</td>
<td>$77.1K</td>
<td>9.2K</td>
<td>3.0K</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$1.53</td>
<td>$1.49</td>
<td>$1.52</td>
<td>$62.00</td>
<td>$76.0K</td>
<td>9.2K</td>
<td>3.5K</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$1.44</td>
<td>$1.4</td>
<td>$1.43</td>
<td>$62.00</td>
<td>$71.5K</td>
<td>9.2K</td>
<td>1.5K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Citigroup</h3>
<p>Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.</p>
<p>In light of the recent options history for Citigroup, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Citigroup</h3>
<ul>
<li>With a trading volume of 734,961, the price of C is up by 0.35%, reaching $62.88.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 74 days from now.</li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Citigroup with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Check Out What Whales Are Doing With Citigroup

<p>Ratings for Gaming and Leisure Props (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPI#NASDAQ">GLPI</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $50.33, with a high estimate of $53.00 and a low estimate of $47.00. A decline of 0.83% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399288_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive Gaming and Leisure Props is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Ronald Kamdem</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Mitch Germain</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$53.00</td>
<td>-</td>
</tr>
<tr>
<td>Brad Heffern</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$49.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Mitch Germain</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$53.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Gaming and Leisure Props. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Gaming and Leisure Props compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Gaming and Leisure Props's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Gaming and Leisure Props's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GLPI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Gaming and Leisure Props analyst ratings.</strong></a></p>
<h2>Delving into Gaming and Leisure Props's Background</h2>
<p>Gaming and Leisure Properties Inc, or GLP, is a real estate investment property trust whose primary business consists of acquiring, financing, and owning real estate property to be leased to gaming operators in triple-net lease arrangements. The GLPI's portfolio consisted of interests in sixty one gaming and related facilities, the real property associated with thirty four gaming and related facilities operated by PENN, the real property associated with six gaming and related facilities operated by Caesars Entertainment Corporation.</p>
<h3>Breaking Down Gaming and Leisure Props's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Gaming and Leisure Props's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of <strong>5.84%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Gaming and Leisure Props's net margin excels beyond industry benchmarks, reaching <strong>46.38%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Gaming and Leisure Props's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.21%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Gaming and Leisure Props's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>1.48%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Gaming and Leisure Props's debt-to-equity ratio is below the industry average. With a ratio of <b>1.67</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GLPI

Critical Insights From Gaming and Leisure Props Analyst Ratings: What You Need To Know

<p>Providing a diverse range of perspectives from bullish to bearish, 18 analysts have published ratings on Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) in the last three months.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $131.89, a high estimate of $190.00, and a low estimate of $103.00. This current average has increased by 6.52% from the previous average price target of $123.82. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399281_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A clear picture of Axsome Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$107.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$109.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$128.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$108.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Buy</td>
<td>$108.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$123.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$103.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$108.00</td>
<td>-</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$111.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Axsome Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Axsome Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Axsome Therapeutics analyst ratings.</strong></a></p>
<h2>Get to Know Axsome Therapeutics Better</h2>
<p>Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.</p>
<h3>Axsome Therapeutics: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Axsome Therapeutics showcased positive performance, achieving a revenue growth rate of <strong>193.5%</strong> as of 31 December, 2023. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Axsome Therapeutics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-137.92%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Axsome Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-42.85%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Axsome Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-16.59%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Axsome Therapeutics's debt-to-equity ratio is below the industry average at <strong>0.98</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AXSM

Peeling Back The Layers: Exploring Axsome Therapeutics Through Analyst Insights

<p><i>Romil Bahl to step down and Ronald Totton named as Interim President and CEO</i></p>
<p>ATLANTA, April 29, 2024 /PRNewswire/ -- KORE Group Holdings, Inc. <strong>(NYSE:</strong><a href="https://www.benzinga.com/stock/KORE#NYSE"><strong>KORE</strong></a><strong>)</strong> ("KORE," the "Company," "we" or "our"), a global leader in Internet of Things ("IoT") Solutions and pioneering IoT hyperscaler, and provider of IoT Connectivity, Solutions and Analytics, announced today that Romil Bahl will be stepping down as President and Chief Executive Officer and that the Company's Board of Directors (the "Board") has named Ronald Totton as the Company's Interim President and Chief Executive Officer, effective May 3, 2024.</p>
<p>Romil Bahl has served as KORE's President and CEO since 2017.&nbsp; He has led the KORE 3.0 Vision and Growth Strategy that has enabled the Company to triple the number of IoT Connected Devices it supports globally, expanded its portfolio of services, and guided KORE to five consecutive years in the Gartner Leaders quadrant for IoT-managed services. Mr. Bahl also led the transformation of the Company resulting in KORE's listing on the New York Stock Exchange. In mutual agreement with the Board, he will transition from his role as President and CEO on May 3, 2024.</p>
<p>"Romil has been a fantastic leader for us," said Tim Donahue, Chairman of the Board. "From our first meeting back in 2020, I have had the utmost respect for Romil's work ethic and integrity, his strategic thinking, and his focus on the customer value proposition."</p>
<p>"It has been an honor and a privilege to lead KORE over the last six and a half years," said Mr. Bahl. &nbsp;"I would like to thank our global team of IoTers, without whom none of our successes would have been possible. KORE is now well positioned for the Decade of IoT, with an industry-leading eSIM proposition, pre-configured solutions in health, fleet, and high bandwidth applications, and a one-stop shop of services that help simplify IoT deployments."</p>
<p>Mr. Totton, who will succeed Mr. Bahl, brings nearly three decades of strategy, finance, sales, and leadership experience to the President and CEO role at KORE, including many years in the Technology, Media, and Telecoms sector. Prior to joining KORE, Mr. Totton served as Chief Executive Officer of ST Telemedia Cloud (Temasek Holdings) and Executive Vice President, Corporate Development at ST Telemedia Group. &nbsp;He previously held leadership roles at BT Global Services, including Chief Executive Officer, Northern, Central and Eastern Europe, and Russia as well as Managing Director, South East Asia.&nbsp; In addition to his executive roles, Totton held a number of Directorship roles for both ST Telemedia Group and BT Global Services.</p>
<p>"Ron is an accomplished executive in the telecom sector and beyond," said Mr. Donahue. "He has a track record of leading innovative businesses toward growth and transformation, and he will serve KORE's stakeholders well. We are very fortunate to have a leader of Ron's caliber join the KORE team."</p>
<p>Mr. Totton stated, "KORE has long been recognized as a pioneer in the IoT space – an innovative and flexible partner that creates meaningful impact for customers. &nbsp;KORE's next chapter builds on this foundation to even better serve our customers and deliver enhanced value for stockholders.&nbsp; There are incredible opportunities ahead for the company and this team." &nbsp;Mr. Totton today joins the Company as an executive advisor until May 3, 2024, when he will assume the role of interim President and CEO.</p>
<p>KORE's management change is not the result of any material or unexpected financial events.</p>


Management

KORE

KORE Announces President And CEO Transition; Romil Bahl To Step Down And Ronald Totton Named As Interim President And CEO, Effective May 3, 2024

<p>Throughout the last three months, 12 analysts have evaluated ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $145.58, a high estimate of $170.00, and a low estimate of $120.00. This upward trend is evident, with the current average reflecting a 4.73% increase from the previous average price target of $139.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714399240_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive ConocoPhillips. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$160.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$154.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Ryan Todd</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$157.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Paul Cheng</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$149.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$158.00</td>
<td>-</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$170.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Devin McDermott</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$129.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$139.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Ryan Todd</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$133.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$143.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Paul Cheng</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to ConocoPhillips. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of ConocoPhillips compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of ConocoPhillips's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into ConocoPhillips's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/COP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on ConocoPhillips analyst ratings.</strong></a></p>
<h2>About ConocoPhillips</h2>
<p>ConocoPhillips is a US-based independent exploration and production firm. In 2023, it produced 1.2 million barrels per day of oil and natural gas liquids and 3.1 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2023 were 6.8 billion barrels of oil equivalent.</p>
<h3>ConocoPhillips's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, ConocoPhillips faced challenges, resulting in a decline of approximately <strong>-20.63%</strong> in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> ConocoPhillips's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>20.18%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> ConocoPhillips's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>6.13%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> ConocoPhillips's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>3.14%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> ConocoPhillips's debt-to-equity ratio is below the industry average at <strong>0.38</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Decoding 12 Analyst Evaluations For ConocoPhillips

Epsilon Healthcare

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Epsilon Healthcare Stock (OTC:HDRPF)

Thursday, January 30, 2020